Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1966 to 1980 of 9039 results

  1. Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [GID-TA12039]

    Awaiting development Reference number: GID-TA12039 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Serplulimab with carboplatin and nab-paclitaxel for untreated advanced squamous non-small cell lung cancer [GID-TA12040]

    Awaiting development Reference number: GID-TA12040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]

    Awaiting development Reference number: GID-TA12038 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [GID-TA12033]

    Awaiting development Reference number: GID-TA12033 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  7. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [GID-TA11987]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [GID-TA11976]

    Awaiting development Reference number: GID-TA11976 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. NICE Funding Variation Request Consultation: methods / process manual consultation

    We are listening to your views on this NICE process and methods. Comments close 19 June 2026.

    In consultation

  13. Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  14 July 2026

    Technology appraisal guidance
    Awaiting development